Diagnosis and Treatment Strategy Optimization of Severe Pneumonia Based on Multi-omics Data Integration

Recruiting

• Conditions: Severe Community-acquired Pneumonia
• Interventions: Diagnostic Test: Multi-omics tests

• Registration Number: NCT06288074
• Lead Sponsor: Capital Medical University

Brief Summary

Severe community-acquired pneumonia still has a high incidence and mortality, but the molecular mechanism and prognostic biomarkers of severe community-acquired pneumonia caused by different pathogens are still unclear, and the best treatment strategy has not been determined. Based on this, this project intends to take patients with severe community-acquired pneumonia caused by different pathogens as the research object, explore the molecular mechanism of severe community-acquired pneumonia from multiple angles, integrate relevant research data to evaluate the rationality of initial empirical medication, and lay the foundation for precise treatment of severe pneumonia. The research results will help to develop a new rapid and accurate target for clinical diagnosis and efficacy evaluation of severe pneumonia, and build a precise treatment system for severe pneumonia.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2024-01-03
• Status Verified: 2024-02
• Study First Submitted QC: 2024-02-24
• Last Update Submitted: 2024-02-24
• Study First Posted: 2024-03-01
• Last Update Posted: 2024-03-01
• Study Start: 2024-03-10
• Primary Completion: 2024-12-31
• Study Completion: 2024-12-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

Age> 18 years old

Clinical diagnosis of community-acquired pneumonia

Exclusion Criteria

Pregnancy, perinatal and lactating women

Combined immunosuppressive diseases: such as HIV, solid organ transplantation, solid organ/hematologic malignant tumor chemotherapy, rheumatic diseases or glomerular diseases need to take hormone/immunosuppressant therapy

Combined blood system diseases: such as leukemia reactions, aplastic anemia, neutropenia or deficiency of granulocytes, previous bone marrow/stem cell transplantation

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Non-Severe community-acquired pneumonia	Multi-omics tests	-
Severe community-acquired pneumonia	Multi-omics tests	-
Healthy control	Multi-omics tests	-

Primary Outcome Measures

Name	Time	Method
Hospital mortality	during hospitalization (up to day 14)

Secondary Outcome Measures

Name	Time	Method
Length of ICU stay	during hospitalization (up to day 14)
Expense during hospitalization	during hospitalization (up to day 14)	All expenses incurred in hospitalization, including bed fee, examination fee, operation or treatment fee.
Cause of death	during hospitalization (up to day 14)
Length of stay	during hospitalization (up to day 14)

Trial Locations

Locations (1)

Beijing Institute of Respiratory Medicine; 🇨🇳 Beijing, Beijing, China